This trial is active, not recruiting.

Conditions type 1 diabetes, children
Treatment umbilical cord blood vita 34
Phase phase 1
Sponsor Technische Universität München
Start date September 2008
End date September 2014
Trial size 18 participants
Trial identifier NCT00989547, 593


Type 1 diabetes (T1D) is still associated with tremendous morbidity and premature mortality.

Patients require multiple daily insulin injections throughout their lives as well as close monitoring of their diet and blood sugar levels to prevent complications. Unfortunately, there is presently no permanent cure for diabetes. Whole pancreas or islet cell transplantation is available only to a very limited number of patients and necessitates potential lifelong immunosuppressive therapy. Autologous stem cell transplants have been used successfully for ALL (acute lymphoblastic leukemia), AML (acute myeloblastic leukemia) and for the treatment of a variety of cancers including breast cancer and neuroblastomas, and more recently for the treatment of autoimmune disorders such as multiple sclerosis (MS), lupus-like disease, and rheumatic disorders. Recently it was shown that bone marrow-derived stems cells transplanted into diabetic mice led to reduced hyperglycemia within 7 days after transplantation and was sustained until they were sacrificed at 35 days post-transplantation. The investigators' goal is to transfuse autologous umbilical cord blood into 23 children (Germany 10 and 20 Controls) with T1D in an attempt to regenerate pancreatic islet insulin producing beta cells and improve blood glucose control. As secondary goals, the investigators aim to track the migration of transfused cord blood stem and study the potential changes in metabolism/immune function leading to islet regeneration.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation non-randomized
Intervention model parallel assignment
Masking open label
Primary purpose treatment
(Active Comparator)
umbilical cord blood vita 34
Intervention type: Autologous Umbilical Cord Blood Transfusion
(No Intervention)

Primary Outcomes

insulin production
time frame:

Secondary Outcomes

Insulin Dose, Autoantibody levels, T-cell functional response assays, Cytokine levels
time frame:

Eligibility Criteria

Male or female participants at least 1 year old.

Inclusion Criteria: - Must have a diagnosis of T1D and have stored umbilical cord blood (10 patients sought) at the cord bank Vita 34. - TID diagnosis will be defined as having a clear history of polydipsia, polyphagia, polyuria, and weight loss consistent with a clinical diagnosis, diagnosis will mot be based solely upon the presence of autoantibodies. - Cord blood meets all selection and testing criteria (see below). - Normal screening values for CBC, Renal function and electrolytes (BMP). - Willing to comply with intensive diabetes management - Not younger than 1 year of age Exclusion Criteria: - Have complicating medical issues that would interfere with blood drawing or monitoring. - Require chronic use of steroids or other immunosuppressive agents for other conditions. - Cord Blood with viability < 50%. - Positive infectious disease markers from mothers blood or cord at time of collection (See below for details). - Any evidence of illness on planned infusion date (i.e. fever >38.5 C, vomiting, diarrhea, wheezing, or crackles).

Additional Information

Official title Transfusion of Autologous Umbilical Cord Blood to Reverse Hyperglycemia in Children With Type 1 Diabetes - A Pilot Study.
Trial information was received from ClinicalTrials.gov and was last updated in July 2013.
Information provided to ClinicalTrials.gov by Technische Universität München.